Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Titel:
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Auteur:
Earl, Helena M Hiller, Louise Dunn, Janet A Blenkinsop, Clare Grybowicz, Louise Vallier, Anne-Laure Abraham, Jean Thomas, Jeremy Provenzano, Elena Hughes-Davies, Luke Gounaris, Ioannis McAdam, Karen Chan, Stephen Ahmad, Rizvana Hickish, Tamas Houston, Stephen Rea, Daniel Bartlett, John Caldas, Carlos Cameron, David A Hayward, Larry
Verschenen in:
Lancet oncology
Paginering:
Jaargang 16 (2015) nr. 6 pagina's 11 p.
Jaar:
2015
Inhoud:
Uitgever:
Earl et al. Open Access article distributed under the terms of CC BY-NC-ND